AbCellera Biologics (NASDAQ:ABCL – Get Free Report) and Kura Oncology (NASDAQ:KURA – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.
Risk and Volatility
AbCellera Biologics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500.
Institutional & Insider Ownership
61.4% of AbCellera Biologics shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by insiders. Comparatively, 7.6% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AbCellera Biologics | $75.13 million | 46.56 | -$146.41 million | ($0.54) | -21.13 |
| Kura Oncology | $67.48 million | 14.90 | -$278.67 million | ($3.37) | -3.35 |
AbCellera Biologics has higher revenue and earnings than Kura Oncology. AbCellera Biologics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares AbCellera Biologics and Kura Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AbCellera Biologics | -248.83% | -17.49% | -12.36% |
| Kura Oncology | -384.30% | -207.18% | -45.17% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for AbCellera Biologics and Kura Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AbCellera Biologics | 1 | 1 | 4 | 1 | 2.71 |
| Kura Oncology | 1 | 1 | 10 | 0 | 2.75 |
AbCellera Biologics currently has a consensus price target of $12.83, suggesting a potential upside of 12.47%. Kura Oncology has a consensus price target of $25.40, suggesting a potential upside of 124.78%. Given Kura Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than AbCellera Biologics.
Summary
AbCellera Biologics beats Kura Oncology on 11 of the 15 factors compared between the two stocks.
About AbCellera Biologics
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
About Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
